Log in to save to my catalogue

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐li...

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐li...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0e9bc75e14647f5afcebfe007cf88f5

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

About this item

Full title

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

Publisher

Melbourne: John Wiley & Sons Australia, Ltd

Journal title

Thoracic cancer, 2021-07, Vol.12 (14), p.2113-2121

Language

English

Formats

Publication information

Publisher

Melbourne: John Wiley & Sons Australia, Ltd

More information

Scope and Contents

Contents

Background
A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized phase II trial, was designed to assess the benefit of maintenance therapy in patients with ED‐SCLC who res...

Alternative Titles

Full title

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c0e9bc75e14647f5afcebfe007cf88f5

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0e9bc75e14647f5afcebfe007cf88f5

Other Identifiers

ISSN

1759-7706

E-ISSN

1759-7714

DOI

10.1111/1759-7714.14048

How to access this item